title: PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
abstract: Primary central nervous system (CNS) lymphoma (PCNSL) and primary testicular lymphoma (PTL) are rare extranodal large B-cell lymphomas with similar genetic signatures. There are no standard-of-care treatment options for patients with relapsed and refractory PCNSL and PTL, and the overall prognosis is poor. PCNSLs and PTLs exhibit frequent 9p24.1 copy-number alterations and infrequent translocations of 9p24.1 and associated increased expression of the programmed cell death protein 1 (PD-1) ligands, PD-L1 and PD-L2. The activity of PD-1 blockade in other lymphomas with 9p24.1 alterations prompted us to test the efficacy of the anti-PD1 antibody, nivolumab, in 4 patients with relapsed/refractory PCNSL and 1 patient with CNS relapse of PTL. All 5 patients had clinical and radiographic responses to PD-1 blockade, and 3 patients remain progression-free at 13+to 17+months. Our data suggest that nivolumab is active in relapsed/refractory PCNSL and PTL and support further investigation of PD-1 blockade in these diseases.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA.|Brigham and Women's Hospital, Boston, MA; and.
authors.forename: Lakshmi
authors.initials: L
authors.lastname: Nayak
authors.affiliation: New York Presbyterian Hospital, New York, NY.
authors.forename: Fabio M
authors.initials: FM
authors.lastname: Iwamoto
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA.|Brigham and Women's Hospital, Boston, MA; and.
authors.forename: Ann
authors.initials: A
authors.lastname: LaCasce
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA.|Brigham and Women's Hospital, Boston, MA; and.
authors.forename: Srinivasan
authors.initials: S
authors.lastname: Mukundan
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA.
authors.forename: Margaretha G M
authors.initials: MGM
authors.lastname: Roemer
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA.
authors.forename: Bjoern
authors.initials: B
authors.lastname: Chapuy
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA.|Brigham and Women's Hospital, Boston, MA; and.
authors.forename: Philippe
authors.initials: P
authors.lastname: Armand
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA.|Brigham and Women's Hospital, Boston, MA; and.
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Rodig
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA.|Brigham and Women's Hospital, Boston, MA; and.
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Shipp
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000000981:diagnostic imaging / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000628:therapy; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000276:immunology; D013736:Testicular Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab